Nephros Price to Book Ratio 2011-2025 | NEPH
Historical price to book ratio values for Nephros (NEPH) over the last 10 years. The current price to book ratio for Nephros as of November 14, 2025 is 4.66.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Nephros Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2025-11-14 | 4.40 | 4.86 | |
| 2025-06-30 | 4.09 | $0.91 | 4.52 |
| 2025-03-31 | 1.72 | $0.88 | 1.96 |
| 2024-12-31 | 1.47 | $0.81 | 1.81 |
| 2024-09-30 | 1.71 | $0.78 | 2.21 |
| 2024-06-30 | 2.11 | $0.75 | 2.81 |
| 2024-03-31 | 2.19 | $0.78 | 2.82 |
| 2023-12-31 | 3.46 | $0.79 | 4.36 |
| 2023-09-30 | 1.48 | $0.82 | 1.80 |
| 2023-06-30 | 1.55 | $0.83 | 1.88 |
| 2023-03-31 | 1.07 | $0.85 | 1.26 |
| 2022-12-31 | 1.16 | $0.86 | 1.34 |
| 2022-09-30 | 0.91 | $0.93 | 0.98 |
| 2022-06-30 | 1.53 | $1.21 | 1.26 |
| 2022-03-31 | 4.40 | $1.30 | 3.39 |
| 2021-12-31 | 5.90 | $1.44 | 4.10 |
| 2021-09-30 | 8.77 | $1.50 | 5.85 |
| 2021-06-30 | 10.15 | $1.49 | 6.83 |
| 2021-03-31 | 6.65 | $1.56 | 4.26 |
| 2020-12-31 | 8.58 | $1.58 | 5.44 |
| 2020-09-30 | 7.23 | $1.27 | 5.71 |
| 2020-06-30 | 8.39 | $1.36 | 6.18 |
| 2020-03-31 | 6.30 | $1.51 | 4.17 |
| 2019-12-31 | 9.95 | $0.95 | 10.43 |
| 2019-09-30 | 8.05 | $0.86 | 9.32 |
| 2019-06-30 | 5.49 | $0.89 | 6.19 |
| 2019-03-31 | 4.32 | $0.78 | 5.53 |
| 2018-12-31 | 5.13 | $0.95 | 5.42 |
| 2018-09-30 | 5.43 | $0.99 | 5.47 |
| 2018-06-30 | 5.47 | $0.63 | 8.67 |
| 2018-03-31 | 3.78 | $0.30 | 12.65 |
| 2017-12-31 | 4.05 | $0.32 | 12.76 |
| 2017-09-30 | 2.70 | $0.04 | 61.36 |
| 2017-06-30 | 2.07 | $0.13 | 15.90 |
| 2017-03-31 | 3.46 | $0.23 | 15.14 |
| 2016-12-31 | 3.29 | $0.12 | 27.32 |
| 2016-09-30 | 3.33 | $0.22 | 14.96 |
| 2016-06-30 | 2.31 | $0.31 | 7.50 |
| 2016-03-31 | 2.34 | $0.37 | 6.37 |
| 2015-12-31 | 1.94 | $0.49 | 3.93 |
| 2015-09-30 | 3.33 | $0.56 | 5.97 |
| 2015-06-30 | 6.39 | $-1.66 | -3.86 |
| 2015-03-31 | 5.40 | $-1.60 | -3.37 |
| 2014-12-31 | 7.11 | $-1.68 | -4.23 |
| 2014-09-30 | 6.98 | $-0.14 | -50.69 |
| 2014-06-30 | 10.62 | $0.08 | 137.74 |
| 2014-03-31 | 5.76 | $0.27 | 21.08 |
| 2013-12-31 | 3.82 | $-1.85 | -2.06 |
| 2013-09-30 | 10.80 | $0.21 | 50.33 |
| 2013-06-30 | 8.10 | $0.42 | 19.24 |
| 2013-03-31 | 7.11 | $-1.27 | -5.60 |
| 2012-12-31 | 10.71 | $-0.45 | -23.90 |
| 2012-09-30 | 12.60 | $0.25 | 50.40 |
| 2012-06-30 | 18.00 | $0.71 | 25.38 |
| 2012-03-31 | 9.45 | $0.87 | 10.81 |
| 2011-12-31 | 6.21 | $1.22 | 5.10 |
| 2011-09-30 | 17.10 | 0.00 | |
| 2011-06-30 | 6.75 | 0.00 | |
| 2011-03-31 | 3.96 | 0.00 | |
| 2010-12-31 | 18.00 | $0.56 | 32.17 |
| 2010-09-30 | 50.40 | 0.00 | |
| 2010-06-30 | 64.80 | 0.00 | |
| 2010-03-31 | 198.00 | 0.00 | |
| 2009-12-31 | 140.40 | $8.44 | 16.64 |
| 2009-09-30 | 255.60 | 0.00 | |
| 2009-06-30 | 194.40 | 0.00 | |
| 2009-03-31 | 18.00 | 0.00 | |
| 2008-12-31 | 21.42 | $11.93 | 1.79 |
| 2008-09-30 | 75.60 | 0.00 | |
| 2008-06-30 | 120.60 | 0.00 | |
| 2008-03-31 | 153.00 | 0.00 | |
| 2007-12-31 | 90.00 | $41.27 | 2.18 |
| 2007-09-30 | 237.60 | 0.00 | |
| 2007-06-30 | 223.20 | 0.00 | |
| 2007-03-31 | 325.80 | 0.00 | |
| 2006-12-31 | 261.00 | $-30.54 | -8.55 |
| 2006-09-30 | 180.00 | 0.00 | |
| 2006-06-30 | 304.20 | 0.00 | |
| 2006-03-31 | 415.80 | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.047B | $0.014B |
| Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $227.079B | 26.17 |
| EssilorLuxottica (ESLOY) | France | $171.331B | 0.00 |
| Boston Scientific (BSX) | United States | $152.232B | 34.81 |
| Stryker (SYK) | United States | $138.522B | 27.50 |
| Medtronic (MDT) | Ireland | $122.971B | 17.34 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.219B | 0.00 |
| Agilent Technologies (A) | United States | $41.624B | 26.94 |
| ResMed (RMD) | United States | $35.677B | 24.69 |
| GE HealthCare Technologies (GEHC) | United States | $33.321B | 15.94 |
| Koninklijke Philips (PHG) | Netherlands | $27.607B | 18.03 |
| Insulet (PODD) | United States | $23.404B | 72.64 |
| Terumo (TRUMY) | Japan | $22.638B | 25.48 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.819B | 11.11 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.952B | 0.00 |
| Baxter (BAX) | United States | $9.495B | 7.66 |
| Sunny Optical Technology (SNPTF) | China | $9.361B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.447B | 30.37 |
| Demant (WILYY) | Denmark | $7.346B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $3.515B | 10.71 |
| Haemonetics (HAE) | United States | $3.440B | 15.31 |
| ICU Medical (ICUI) | United States | $3.370B | 21.40 |
| Envista Holdings (NVST) | United States | $3.190B | 18.30 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.120B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $2.886B | 13.16 |
| LeMaitre Vascular (LMAT) | United States | $2.006B | 40.38 |
| Perrigo (PRGO) | Ireland | $1.896B | 4.75 |
| Phibro Animal Health (PAHC) | United States | $1.828B | 18.26 |
| AtriCure (ATRC) | United States | $1.636B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.450B | 9.32 |
| Neogen (NEOG) | United States | $1.389B | 26.62 |
| Curaleaf Holdings (CURLF) | Canada | $1.385B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.287B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.245B | 18.02 |
| Tilray Brands (TLRY) | Canada | $1.213B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.195B | 52.36 |
| BioLife Solutions (BLFS) | United States | $1.159B | 343.86 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.931B | 0.00 |
| InMode (INMD) | Israel | $0.896B | 10.12 |
| Valneva SE (VALN) | France | $0.778B | 0.00 |
| Surmodics (SRDX) | United States | $0.595B | 0.00 |
| Omeros (OMER) | United States | $0.558B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.495B | 17.03 |
| CeriBell (CBLL) | United States | $0.479B | 0.00 |
| Evolus (EOLS) | United States | $0.468B | 0.00 |
| SNDL (SNDL) | Canada | $0.441B | 0.00 |
| BillionToOne (BLLN) | $0.402B | 0.00 | |
| Cresco Labs (CRLBF) | United States | $0.344B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.340B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Cerus (CERS) | United States | $0.311B | 0.00 |
| Brainsway (BWAY) | Israel | $0.308B | 52.53 |
| Sanuwave Health (SNWV) | United States | $0.283B | 0.00 |
| Quanterix (QTRX) | United States | $0.268B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.257B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.256B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.244B | 143.67 |
| Viemed Healthcare (VMD) | United States | $0.243B | 19.36 |
| High Tide (HITI) | Canada | $0.236B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.227B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Exagen (XGN) | United States | $0.204B | 0.00 |
| Organigram Global (OGI) | Canada | $0.204B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.192B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.178B | 15.64 |
| FitLife Brands (FTLF) | United States | $0.170B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.166B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.157B | 0.00 |
| Apyx Medical (APYX) | United States | $0.149B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.126B | 0.00 |
| Biote (BTMD) | United States | $0.115B | 5.04 |
| Quipt Home Medical (QIPT) | United States | $0.100B | 0.00 |
| MacroGenics (MGNX) | United States | $0.095B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 0.00 |
| Fonar (FONR) | United States | $0.091B | 13.25 |
| Sharps Technology (STSS) | United States | $0.087B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.081B | 0.00 |
| Agape ATP (ATPC) | $0.067B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.049B | 20.77 |
| Cytosorbents (CTSO) | United States | $0.041B | 0.00 |
| Jin Medical (ZJYL) | China | $0.040B | 0.00 |
| Veru (VERU) | United States | $0.037B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Modular Medical (MODD) | United States | $0.029B | 0.00 |
| Bonk (BNKK) | United States | $0.029B | 0.00 |
| United-Guardian (UG) | United States | $0.028B | 14.30 |
| Zynex (ZYXI) | United States | $0.017B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.012B | 0.00 |
| INLIF (INLF) | China | $0.010B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Flora Growth (FLGC) | United States | $0.006B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Functional Brands (MEHA) | $0.003B | 0.00 | |
| Akanda (AKAN) | Canada | $0.001B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |